REG - Shield Therapeutics - Result of AGM

Shield TherapeuticsAnnouncement

22/05/2025 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250522:nRSV8612Ja&default-theme=true

RNS Number : 8612J  Shield Therapeutics PLC  22 May 2025

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Results of 2025 Annual General Meeting

 

London, UK, 22 May, 2025:  Shield Therapeutics plc (LSE: STX), a commercial
stage pharmaceutical company specialising in iron deficiency with or without
anemia ("ID/IDA"), announces the voting results for each resolution set out in
the Notice of Annual General Meeting 2025. The Board reports that all
resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12
passed as special resolutions.

 

The following table shows the votes cast on each resolution:

 

                VOTES        %       VOTES AGAINST  %      WITHHELD VOTES

FOR
 Resolution 1   668,835,432  99.98%  133,164        0.02%  357,039
 Resolution 2   668,122,080  99.89%  757,837        0.11%  445,718
 Resolution 3   668,296,332  99.91%  583,585        0.09%  445,718
 Resolution 4   668,137,993  99.89%  741,976        0.11%  445,666
 Resolution 5   668,388,581  99.93%  491,388        0.07%  445,666
 Resolution 6   668,133,181  99.89%  741,976        0.11%  450,478
 Resolution 7   667,890,103  99.85%  1,027,158      0.15%  408,374
 Resolution 8   668,672,292  99.96%  291,492        0.04%  361,851
 Resolution 9   666,908,073  99.69%  2,080,523      0.31%  337,039
 Resolution 10  666,442,645  99.60%  2,643,451      0.40%  239,539
 Resolution 11  666,424,128  99.88%  808,577        0.12%  2,092,930
 Resolution 12  666,417,127  99.88%  793,851        0.12%  2,114,657

 

Notes:

1.   Number of shares in issue 1,041,690,484.

2.   Details of the votes received on the resolutions are available on the
Company's website:

https://www.shieldtherapeutics.com/corporate-documents/
(https://www.shieldtherapeutics.com/corporate-documents/) .

3.   Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

 

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                                                                          Investorrelations@shieldtx.com

 Stephanie Hicks, Investor Relations

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel                                                                                    +44 (0)20 7418 8900

 Joint Broker                                                                                   +44 (0)20 7220 0500
 Cavendish Ltd
 Geoff Nash / Rory Sale / Nigel Birks / Harriet
 Ward

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients.

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
commercially launched its lead product ACCRUFeR® in the U.S. through an
exclusive, multi-year collaboration with a commercial partner.
Internationally, it has secured licensing agreements with four specialty
pharmaceutical companies, enabling commercialisation across key markets. The
product is currently marketed in the UK, European Union, Australia, and New
Zealand as FeRACCRU®, with additional exclusive partnerships in place for
China and surrounding regions, South Korea, and as ACCRUFeR® in Canada.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPKBBKABKDPPB